Entera Bio Ltd.
ENTX · XNASCIK 1638097fmd_10WJAXVYJVJZPK2MBMN6SWCP1FManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 30 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Cost of revenue | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 3 | 3 | 9 | 7 | 6 | 7 | 6 | 5 | 4 | 6 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | 0 | 0 |
| Total operating expenses | – | – | – | – | 11 | 12 | 13 | 9 | 10 | 12 |
| Compensation and benefits | – | – | – | – | – | – | – | – | 1 | 2 |
| Operating income | (5) | (11) | (11) | (11) | (11) | (12) | (13) | (9) | (10) | (12) |
| Other non-operating income (expense) | – | – | – | – | (0) | (0) | 0 | 0 | 0 | 0 |
| Income before taxes | – | – | (10) | (11) | (11) | (12) | (13) | (9) | (10) | (11) |
| Income tax expense | – | – | – | – | 0 | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (11) | (12) | (13) | (9) | (10) | (11) |
| Net income | (1) | (11) | (10) | (11) | (11) | (12) | (13) | (9) | (10) | (11) |